Eli Lilly and Company (LLY)vsViking Holdings Ltd (VIK)
LLY
Eli Lilly and Company
$878.24
-2.09%
HEALTHCARE · Cap: $808.22B
VIK
Viking Holdings Ltd
$68.58
-4.20%
CONSUMER CYCLICAL · Cap: $32.40B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 903% more annual revenue ($65.18B vs $6.50B). LLY leads profitability with a 31.7% profit margin vs 17.6%. VIK trades at a lower P/E of 28.3x. LLY earns a higher WallStSmart Score of 80/100 (A-).
LLY
Exceptional Buy80
out of 100
Grade: A-
VIK
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+17.6%
Fair Value
$1065.17
Current Price
$878.24
$186.93 discount
Margin of Safety
+36.3%
Fair Value
$120.28
Current Price
$68.58
$51.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Strong operational efficiency at 20.9%
Revenue surging 27.8% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.6x book value
Moderate valuation
2.3% earnings growth
ROE of 2.5% — below average capital efficiency
Trading at 28.0x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : VIK
The strongest argument for VIK centers on Operating Margin, Revenue Growth. Profitability is solid with margins at 17.6% and operating margin at 20.9%. Revenue growth of 27.8% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : VIK
The primary concerns for VIK are P/E Ratio, EPS Growth, Return on Equity.
Key Dynamics to Monitor
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (80/100 vs 66/100), backed by strong 31.7% margins and 42.6% revenue growth. VIK offers better value entry with a 36.3% margin of safety. Both earn "Exceptional Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Viking Holdings Ltd
CONSUMER CYCLICAL · TRAVEL SERVICES · USA
Viking Holdings Ltd engages in the passenger shipping and other forms of passenger transport in North America, the United Kingdom, and internationally. The company is headquartered in Pembroke, Bermuda.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?